Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06772870 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 21, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 2025 to Sep 2025
    • Study completion date: Sep 2025 to Dec 2025
    • Start date: Jan 2025 to Feb 2025
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.
Trial Details
NCT Number NCT06772870
Lead Sponsor Design Therapeutics, Inc.
Conditions
(from sponsor)		 Friedreich Ataxia
Related terms Friedreich Ataxia
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov